Clinical Trials Browser

Colonic Neoplasms, Rectal Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Ovarian Neoplasms

Rectal Neoplasms

HER2-low Breast Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

Colorectal Cancer Metastatic

Brain Neoplasms, Glioma, Radiation Injuries

Carcinoma, Hepatocellular, Cholangiocarcinoma

Ependymoma, Medulloblastoma, Recurrence

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Glioblastoma, Recurrence

Malignant Ascites

Ovarian Neoplasms

pMMR/MSS Locally Advanced Rectal Cancer

Triple Negative Breast Neoplasms

Rectal Neoplasms

Ovarian Neoplasms

Hepatecellular Carcinoma

Glioblastoma

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Cancer Metastatic

Ovarian Neoplasms

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Oligodendroglioma

Colorectal Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Carcinoma, Renal Cell

Neoplasm Metastasis, Neoplasms

Carcinoma, Hepatocellular

Non-Resectable Pancreas Carcinoma

Small Cell Lung Carcinoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Diseases

BRAF V600 Colorectal Cancer

Carcinoma, Hepatocellular

Nasopharyngeal Neoplasms

Locally Recurrent Rectal Cancer

Clinical Trials

SCOTI

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

TERTIO

TRIBE-C

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

FOBEAR

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

BRAINS

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

MEMMAT

PRELUDE

SBRT With Atezo/Bev for HCC

MOMENTUM-1

Phenix

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

PRIDE

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

BASKETⅢ

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Autophagy Maintenance (AUTOMAIN)

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

TRIFLUOX-DP

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

AtezoTRIBE2

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

International Multicentric Study ARON-1

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

ATTACH

Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

BELIEVE

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

(HCC)

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

AB-LATE02

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)